AcouSort to present at Redeye’s theme event Tools and Supplies in Life Science 2025
17 september, 13:30
AcouSort AB (publ) today announced its CEO Dr. Torsten Freltoft will present the company and its latest developments at Redeye’s theme event Tools and Supplies in Life Science 2025 on Tuesday, September 23, 2025, at 11:35 CEST.
After the presentation, held in English, there will be a Q&A session, moderated by a Redeye analyst.
This annual event, which gathers leading Swedish companies within the sector to present their outlook, technologies, business opportunities, and risks, will be streamed live on Redeye’s platform. Here viewers can submit questions via a form on the event page. LINK.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.
Attachments
AcouSort to present at Redeye’s theme event Tools and Supplies in Life Science 2025
Ämnen i artikeln
AcouSort to present at Redeye’s theme event Tools and Supplies in Life Science 2025
17 september, 13:30
AcouSort AB (publ) today announced its CEO Dr. Torsten Freltoft will present the company and its latest developments at Redeye’s theme event Tools and Supplies in Life Science 2025 on Tuesday, September 23, 2025, at 11:35 CEST.
After the presentation, held in English, there will be a Q&A session, moderated by a Redeye analyst.
This annual event, which gathers leading Swedish companies within the sector to present their outlook, technologies, business opportunities, and risks, will be streamed live on Redeye’s platform. Here viewers can submit questions via a form on the event page. LINK.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.
Attachments
AcouSort to present at Redeye’s theme event Tools and Supplies in Life Science 2025
Ämnen i artikeln
Aktieanalyser
USA:s nedstängning
-992x558.webp&w=3840&q=75)
Spotify
Aktieråd
Spararnas månad
Aktieanalyser
USA:s nedstängning
Spotify
Aktieråd
Spararnas månad
Marknadsöversikt
1 DAG %
Senast
1 mån
.jpg&w=3840&q=75)
